ClinicalTrials.gg
TerminatedNCT06140407Updated Nov 20, 2026Results posted

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

A Phase 2 interventional study of Cisplatin and Carboplatin in Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer and Stage II Lung Cancer, sponsored by Vanderbilt-Ingram Cancer Center. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Vanderbilt-Ingram Cancer Center · Phase 2, Interventional, and Treatment

How we know · 10 judgments

Why this study was terminated
Low accrual and Merck discontinuing funding and drug supply
Updated Nov 20, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies testing pembrolizumab in Lung Neoplasms — 10 open to participants now, 22 under way, 9 of them phase 3. pembrolizumab · Lung Neoplasms.

Enrollment
37th of 39
1 · median 46
Started
2024
with 6 others
Phase 2
22 of 39
5 open now
Registered
29th of 39
by date

Among the 39 studies testing pembrolizumab in Lung Neoplasms, this one is the 37th largest by enrollment, is one of 7 that started in 2024, is one of 22 in phase 2, and was the 29th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 39 studies testing pembrolizumab in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing pembrolizumab in Lung Neoplasms, or all of them as a file.
02

Study summary

This phase II trial studies how well pembrolizumab after standard treatment with radiation plus the following chemotherapy drugs: cisplatin or carboplatin, plus etoposide works in treating patients with limited stage small cell lung cancer (LS-SCLC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after standard treatment with radiation plus chemotherapy may increase the ability of the immune system to fight LS-SCLC.

Read the detailed description

PRIMARY OBJECTIVE:

I. To investigate progression free survival per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by the investigator in patients with limited stage small cell lung cancer treated with adjuvant pembrolizumab.

SECONDARY OBJECTIVES:

I. Assess median overall survival compared to the historical control dataset (CONVERT trial1) median overall survival (OS) of 30 months.

II. Assess the safety and tolerability of adjuvant pembrolizumab in patients with limited stage SCLC.

EXPLORATORY/TRANSLATIONAL OBJECTIVES:

I. To determine whether patients with detectable circulating tumor deoxyribonucleic acid (ctDNA) after curative intent therapy ("minimal residual disease [MRD] positive") experience shorter median progression free survival (PFS) compared to patients without detectable ctDNA after curative intent therapy ("MRD negative.").

II. Determination of whether patients with ctDNA clearance at any point during curative intent therapy have superior median PFS compared to patients who do not experience ctDNA clearance during curative intent therapy.

OUTLINE:

Patients undergo radiation therapy and receive cisplatin or carboplatin on day 1 of each cycle and etoposide on days 1-3 for 4 cycles. Patients then receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo positron emission tomography (PET) scan during screening. Patients also undergo magnetic resonance imaging (MRI) throughout the trial as well as computed tomography (CT). Additionally, patients undergo blood sample collection throughout the trial.

After completion of study treatment, patients are followed up at 30 days, and every 12 weeks for 2 years.

03

Conditions studied

  • Limited Stage Lung Small Cell Carcinoma
  • Stage I Lung Cancer
  • Stage II Lung Cancer
  • Stage III Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has LS-SCLC (stage I-III, by American Joint Committee on Cancer [AJCC] 8th Edition Cancer Staging) and no evidence of extensive stage disease. Participants may enroll at any time between diagnosis and initiation of definitive concurrent chemoradiation or surgery followed by chemotherapy. Correlative analyses collected during standard of care definitive concurrent chemoradiation or surgery followed by adjuvant chemotherapy are mandatory
  • Male/female participants who are at least 18 years of age on the day of signing with confirmed diagnosis of small cell lung cancer or high grade neuroendocrine carcinoma will be enrolled in this study
  • requirements should conform with Clinical Trials Facilitation and Coordination Group (CTFG) guidelines. The pembrolizumab standard for use of highly effective contraceptive methods for persons of (POCBP) is 120 days (5 half-lives) after the last dose. Please either list the contraception requirement for each compound in the study or use the longest time frame that covers requirements for all compounds in the study
  • Similarly, Company standard for abstaining from breastfeeding after study intervention is at least 5 half-lives. For pembrolizumab, this is 120 days
  • No radiological imaging evidence of disease progression after completion of definitive concurrent chemoradiation or surgery followed by adjuvant chemotherapy
  • The participant (or legally acceptable representative if applicable) provides written informed consent for the trial
  • Have an (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention
  • Participants who are surface antibody (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) anti-viral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization.

Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.

Hepatitis B screening tests are not required unless:

  • Known history of HBV infection
  • As mandated by local health authority

    • Participants with a history of virus (HCV) infection are eligible if HCV viral load is undetectable at screening. Hepatitis C screening tests are not required unless:
  • Known history of HCV infection
  • As mandated by local health authority Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization

    • (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART), defined as:
  • Participants on ART must have a >= 350 cells/mm\^3 at the time of screening
  • Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV ribonucleic acid (RNA) level below 50 or the lower limit of quantitation (LLOQ) (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening
  • It is advised that participants must not have had any acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 12 months.
  • Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (day 1) and agree to continue ART throughout the study
  • The combination ART regimen must not contain any antiretroviral medications that interact with inhibitors/inducers/substrates (https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers)

    • (ANC) >= 1500/uL (specimens must be collected within 10 days prior to the start of study intervention)
    • >= 100000/uL (specimens must be collected within 10 days prior to the start of study intervention)
    • ≥ 9.0 g/dL or ≥ 5.6 mmol/L (specimens must be collected within 10 days prior to the start of study intervention)
  • Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks

    • Creatinine or measured or calculated ( [GFR] can also be used in place of creatinine or creatinine Clearance [CrCl]) =\< 1.5 X (ULN) or >= 30 mL/min for participant with creatinine levels > 1.5 X institutional ULN (specimens must be collected within 10 days prior to the start of study intervention)
  • Creatinine clearance (CrCl) should be calculated per institutional standard

    • Total =\< 1.5 X ULN or direct bilirubin =\< ULN for participants with total bilirubin levels > 1.5 X ULN (specimens must be collected within 10 days prior to the start of study intervention)
    • (AST) (serum glutamic pyruvic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =\< 2.5 X ULN (specimens must be collected within 10 days prior to the start of study intervention)
    • (INR) or prothrombin time (PT) activated partial thromboplastin time (aPTT) =\< 1.5 X ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants (specimens must be collected within 10 days prior to the start of study intervention)

Exclusion criteria

Exclusion Criteria:

  • Has received prior therapy with an , anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
  • Has received prior systemic anti-cancer therapy including agents within 4 weeks prior to allocation
  • Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities requiring , and not have had radiation pneumonitis. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study drug
  • Has received a or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of pembrolizumab
  • Has a known additional that is progressing or requires active treatment. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, localized prostate adenocarcinoma, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score =\< 6, and prostate-specific antigen [PSA]\< 10 ng/mL) untreated in active surveillance with stable disease are not excluded
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has severe (≥ grade 3) to pembrolizumab
  • Has active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment
  • Has had an allogenic tissue/solid organ transplant
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Treatment (pembrolizumab)

    Patients undergo radiation therapy and receive cisplatin or carboplatin on day 1 of each cycle and etoposide on days 1-3 for 4 cycles. Patients then receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan during screening. Patients also undergo MRI throughout the trial as well as CT. Additionally, patients undergo blood sample collection throughout the trial.

    Drug: Cisplatin · Drug: Carboplatin · Drug: Etoposide · Biological: Pembrolizumab · Procedure: Computed Tomography · Procedure: Positron Emission Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Biospecimen Collection · Radiation: Radiation Therapy

Interventions

  • Receive Cisplatin

  • Receive Carboplatin

  • Receive Etoposide

  • BiologicalPembrolizumab

    Receive Pembrolizumab by IV

  • ProcedureComputed Tomography

    Undergo Computed Tomography

  • ProcedurePositron Emission Tomography

    Undergo Positron Emission Tomography

  • ProcedureMagnetic Resonance Imaging

    Undergo Magnetic Resonance Imaging

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

  • RadiationRadiation Therapy

    Undergo Radiation Therapy

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: 13 months

Secondary outcomes

  1. Overall Survival

    Time frame: 13 months

  2. Participants That Had Adverse Events Related to Treatment

    Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0. Adverse events that were attributed to be related to treatment by the treating provider are presented in the table. The highest grade recorded for each adverse event and participant is presented in the table.

    Time frame: 13 months

07

Results

Posted Nov 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Pembrolizumab)
Started1
Completed0
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryProgression-free Survival

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
13 months
Reported as:
Number · months
Progression-free Survival
monthsTreatment (Pembrolizumab)
Progression-free Survival12.62
SecondaryOverall Survival
Time frame:
13 months
Reported as:
Number · months
Overall Survival
monthsTreatment (Pembrolizumab)
Overall Survival12.62
SecondaryParticipants That Had Adverse Events Related to Treatment

Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0. Adverse events that were attributed to be related to treatment by the treating provider are presented in the table. The highest grade recorded for each adverse event and participant is presented in the table.

Time frame:
13 months
Reported as:
Number · participants
Participants That Had Adverse Events Related to Treatment
participantsTreatment (Pembrolizumab)
Arthralgia : Grade 10
Arthralgia : Grade 21
Arthralgia : Grade 30
Arthralgia : Grade 40
Arthralgia : Grade 50
Arthritis : Grade 10
Arthritis : Grade 21
Arthritis : Grade 30
Arthritis : Grade 40
Arthritis : Grade 50
Chills : Grade 11
Chills : Grade 20
Chills : Grade 30
Chills : Grade 40
Chills : Grade 50
Pneumonitis : Grade 11
Pneumonitis : Grade 20
Pneumonitis : Grade 30
Pneumonitis : Grade 40
Pneumonitis : Grade 50
Vasculitis : Grade 11
Vasculitis : Grade 20
Vasculitis : Grade 30
Vasculitis : Grade 40
Vasculitis : Grade 50
Generalized muscle weakness : Grade 11
Generalized muscle weakness : Grade 20
Generalized muscle weakness : Grade 30
Generalized muscle weakness : Grade 40
Generalized muscle weakness : Grade 50
Chronic kidney disease : Grade 10
Chronic kidney disease : Grade 21
Chronic kidney disease : Grade 30
Chronic kidney disease : Grade 40
Chronic kidney disease : Grade 50

Adverse events

Collected over 13 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Pembrolizumab)0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 57
Most frequent other events
EventTreatment (Pembrolizumab)
Abdominal painGastrointestinal disorders1/1
Alanine aminotransferase increasedInvestigations1/1
AlopeciaSkin and subcutaneous tissue disorders1/1
AnemiaBlood and lymphatic system disorders1/1
AnorexiaMetabolism and nutrition disorders1/1
ArthralgiaMusculoskeletal and connective tissue disorders1/1
ArthritisMusculoskeletal and connective tissue disorders1/1
Aspartate aminotransferase increasedInvestigations1/1
Back painMusculoskeletal and connective tissue disorders1/1
Blurred visionEye disorders1/1

Baseline characteristics

Age, Customized
Age, Customized(years)Treatment (Pembrolizumab)
Age at time of consent62
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Pembrolizumab)
Female1
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Pembrolizumab)
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Pembrolizumab)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment (Pembrolizumab)
United States1
08

Study locations

1 site
  • Vanderbilt University/Ingram Cancer Center
    Nashville, Tennessee 37232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in May 2025, 15 months.

Results were first posted in Nov 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2023
First posted
Nov 20, 2023
StartActual
Feb 14, 2024
Primary completionActual
May 27, 2025
CompletionActual
May 27, 2025
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProgression-free survivalSurvivalTime frame: Time from the date of first treatment to progressive disease or death due to any cause, whichever occurs first, assessed up to 3 years → 13 months
Nov 20, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedOverall survivalSurvivalTime frame: Time from the date of first treatment to the date of death due to any cause, assessed up to 3 years → 13 months
  • ChangedBefore Incidence of adverse eventsNow Participants That Had Adverse Events Related to TreatmentTime frame: Up to 3 years → 13 months
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProgression-free survivalSurvivalTime frame: Time from the date of first treatment to progressive disease or death due to any cause, whichever occurs first, assessed up to 3 years → 13 months
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedOverall survivalSurvivalTime frame: Time from the date of first treatment to the date of death due to any cause, assessed up to 3 years → 13 months
    • ChangedBefore Incidence of adverse eventsNow Participants That Had Adverse Events Related to TreatmentTime frame: Up to 3 years → 13 months
    + 3 other changes: index terms, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06140407
Responsible party
Evan Osmundson, MD, PhD (Associate Professor of Medicine, Vanderbilt-Ingram Cancer Center) — Principal investigator
First posted
Nov 20, 2023
Start date
Feb 14, 2024
Primary completion
May 27, 2025
Completion
May 27, 2025
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

Ryan Whitaker, MD, PhD
principal investigator · Vanderbilt University/Ingram Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion